NCCN 2025 Nursing Program: Advancing Oncology Nursing™

March 27, 2025

This program will cover essential updates in clinical oncology practice, including emerging treatment modalities and patient management strategies. Participants will explore evidence-based approaches to supportive care, focusing on symptom management and improving quality of life for patients with cancer. The program will also address the importance of self-care for oncology nurses, providing practical techniques for managing stress and preventing burnout in this challenging field.

Target Audience

This program is designed to meet the educational needs of oncology nurses who treat patients with cancer.

Learning Objectives

Following this program, participants should be able to:

Overall Learning Objectives
•   Discuss advances in the treatment of patients with cancer and key updates in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and apply appropriate treatment and supportive care strategies to optimize patient education and care.
•   Review issues related to Venous Thromboembolism Management in Malignancy; Financial Toxicity of Cancer Care; Hereditary Cancer Syndromes; Remembrance and Renewal: A Holistic Self-Care Program for Oncology Clinicians; Ambulatory Care Models; Updates in Melanoma; and CRS and ICANS Management in CAR T/Bispecific Antibody Therapies.

Venous Thromboembolism Management in Malignancy
•   List the factors that can contribute to enhanced VTE risk, including those that are modifiable.
•   Integrate current prophylactic treatment regimens in patients with cancer at high risk of developing VTE.
•   Describe the common symptoms and treatment options for patients with malignancy that develop VTE.

Financial Toxicity of Cancer Care
•   Define financial toxicity in cancer care including its contributing factors.
•   Identify opportunities for advocacy, treatment adherence, policy change and support services for patients and families.
•   Identify long-term financial impact of cancer treatment on survivors.

Hereditary Cancer Syndromes: MSK CATCH Program (Comprehensive Assessment, Treatment, and Prevention of Cancers with Hereditary Dispositions)
•   Identify the most common hereditary cancer syndromes and associated genetic mutations.
•   Discuss best practices in the surveillance and management of patients. 
•   Examine the role of nurses as part of an interdisciplinary team and the implications for nursing education.

Remembrance and Renewal: A Holistic Self-Care Program for Oncology Clinicians
•   Identify the prevalence, signs and impact of burnout, compassion fatigue and grief in oncology nurses.   
•   Review current evidence-based strategies to improve nursing resilience and well-being.
•   Discuss the implementation and benefits of clinician focused Remembrance and Renewal Programs in cancer centers.

Ambulatory Care Models
•   Describe an ambulatory care model with defined roles/responsibilities.
•   Discuss how ambulatory care models affect patient outcomes.
•   Discuss the importance of ongoing competencies and education to stay up to date with oncology care.

Updates in Melanoma: A Focus on Neoadjuvant Approaches
•   Integrate current neoadjuvant systemic therapy regimens for patients with resectable high-risk stage III nodal and stage IV cutaneous melanoma.
•   Describe the primary advantage(s) of the use of neoadjuvant systemic therapy.
•   Describe how assessment of response to neoadjuvant treatment can help in the personalization of post-operative treatment approaches.

CRS and ICANS Management in CAR T/Bispecific Antibody Therapies
•   Identify symptoms associated with a CRS or ICANS complication post CAR T-cells or bispecific T-cell engagers therapy.
•   Identify nursing interventions to support prompt response to potential CRS and/or ICANS in patients.
•   Identify tools useful in the grading of complications related to these therapies.

You may also be interested in

Supportive Oncology Care

Many health care professionals have had limited education on supportive care topics and have learned on the job. The guidelines and literature continue to advance supportive oncology care.
Additional information
Supporters: 

Supported by educational grants from:

  • AstraZeneca
  • Genentech, a member of the Roche Group
  • Novartis

Supported by an independent medical education grant from ADC Therapeutics.

Supported by a grant from Pfizer Inc.

Course summary
Available credit: 
  • 5.25 ANCC contact hours
    • 2.25 ANCC Pharmacology Contact Hours
  • 5.25 Participation
Course opens: 
03/26/2025
Course expires: 
07/01/2025
Event starts: 
03/27/2025 - 8:00am EDT
Event ends: 
03/27/2025 - 3:00pm EDT
Cost:
$0.00
Add to calendar: 

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have no relevant financial relationships with ineligible companies to disclose.

Lisania (Lisa) Milli, WHNP-BC, MSN, MSCP
Charissa Montgomery, CRNP, MSN, OCN  
Amy E. Rettig, DNP, MALM, MSN, BSN, RN, ACNS-BC, PMHNP-BC
Bayley Sharma, MSN, AGPCNP-BC, PCCN
Andrew Storer, PhD, DNP, RN, NP-C, FAANP
Amanda E. Visnick, RN, BSN, OCN

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated. 

Patricia A. Mangan, MSN, RN, APRN-BC, CRNP
Bristol Myers Squibb: Honoraria
Janssen Pharmaceutica Products, LP: Honoraria
Karyopharm Therapeutics: Honoraria

Krista M. Rubin, MS, FNP-BC
Immunocore Holdings plc: Consulting Fees

NCCN Staff Disclosures

The planner listed below has the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Samantha L. Tamburro, RN, BSN, CPON
Flatiron Health, Inc.: Salary

None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Nurses
NCCN designates this educational activity for a maximum of 5.25 contact hours.

This program offers 2.25 pharmacotherapeutic contact hours for nurses. Eligible sessions are: 

  • Venous Thromboembolism Management in Malignancy
  • Updates in Melanoma
  • CRS and ICANS Management in CAR T/Bispecific Antibody Therapies

Available Credit

  • 5.25 ANCC contact hours
    • 2.25 ANCC Pharmacology Contact Hours
  • 5.25 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Click the Take Course button to start the credit claiming process.
You must be logged in with the same email address used for program registration.

CE credit should be claimed for the program as a whole, not session by session. You may claim credit for the program only one time. When calculating your total credits, you should take into account all of the sessions you viewed either live or via recording. (Please note that you have access to all of the session recordings for 60 days following the live program.) 

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing